Lenire

What Lenire does

Lenire is a Dublin, Ireland-based for-profit private medical device company founded in 2010 that develops a treatment device targeting individuals with severe tinnitus — a condition characterized by persistent ringing or internal noise perception in the ears. With a headcount of 11 to 50 employees, the company operates as a small-to-mid-sized specialty medical device firm, indicating an early-to-mid commercial stage rather than a large-scale enterprise. The product focus is narrow: a single therapeutic device category addressing worse (more severe) tinnitus cases, signaling a concentrated niche strategy rather than a broad audiology or hearing-aid portfolio.

The company's product is a hardware-based therapeutic device marketed under the Lenire brand via its corporate website (lenire.com), the apparent primary commercial channel. The website content was not directly accessible during data collection due to a verification/loading page, so the precise technology stack, proprietary features, regulatory certifications, patent portfolio, and clinical evidence base are not documented in the available input data. The 15-year operating history since 2010 indicates the company has progressed past pure research and development and into commercial availability, although specific milestones — such as regulatory clearances (CE mark, FDA 510(k)/de novo), clinical trial outcomes, and product generations — are not captured in the data set.

The company's business model, go-to-market approach, pricing structure, distribution channels, and revenue mechanics are not disclosed in the available data. As a medical device company selling therapeutic hardware, plausible revenue models include direct-to-consumer sales, healthcare provider partnerships, or distributor relationships, but none of these are confirmed in the input. No funding rounds, revenue figures, customer counts, partnership agreements, or management team information is available. The data set is materially incomplete for a full investment-grade analysis, and the description above reflects only what can be grounded in the firmographic profile and the company's stated product focus.

Name

Lenire

Website

https://lenire.com

Company type

Private

Founded year

2010

Headcount range

11–50 employees

Short description

Lenire is a Dublin, Ireland-based for-profit private medical device company founded in 2010 that develops a treatment device for individuals with severe tinnitus, operating with a small team of 11 to 50 employees.

Ownership category

akta.pro rank

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Core offering

Lenire develops and sells a clinically validated medical device for treating tinnitus. The system uses bimodal neuromodulation, pairing mild electrical stimulation delivered to the tongue tip via an intraoral component with coordinated audio signals played through wireless headphones, administered in structured at-home treatment sessions. The company is headquartered in Dublin, Ireland, and was founded in 2010.

Differentiator

Problem solved

Functional benefit

Products and services

• Lenire Tinnitus Treatment Device

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• WS Audiology (Widex / Signia): WS Audiology combines Widex and Signia, both of which market dedicated tinnitus therapy programs inside their hearing aids and serve audiologists and tinnitus patients worldwide — the same buyer and end-user Lenire targets.
• Demant (Oticon): Demant, parent of Oticon and Bernafon, sells hearing aids with built-in tinnitus sound therapy across global audiology channels and overlaps directly with Lenire on the tinnitus treatment category through audiologist-prescribed solutions.
• Starkey Hearing Technologies: Starkey is a major US hearing-aid manufacturer offering tinnitus management features in its devices, competing with Lenire for the same audiologist channel and tinnitus patient population.
• Cochlear Limited: Cochlear Limited manufactures cochlear implants that are clinically used to address severe tinnitus alongside hearing loss, making it a relevant incumbent in the surgical/prescription-side tinnitus treatment market adjacent to Lenire's device category.
• Sonova (Phonak): Sonova, parent of Phonak and Unitron, is a global hearing-aid incumbent that offers tinnitus therapy features integrated into its hearing aids, addressing the same end-patient via the same audiology channel and competing for the same prescriber budget.

Direct peers

• Otoharmonics (Levo System): Otoharmonics developed the Levo System, another FDA-cleared prescription medical device specifically for tinnitus treatment, making it the closest direct competitor to Lenire's bimodal neuromodulation device in product category, regulatory pathway, and target clinicians/patients.

Others

• Neuromod Devices: Neuromod Devices is the Ireland-based developer of the Lenire tinnitus treatment device itself; it is included as the immediate corporate/technology counterpart that defines Lenire's product technology and clinical positioning.

Emerging players

• Natus Medical: Natus Medical supplies neurology and ENT diagnostic and therapeutic devices, including neurostimulation and evoked-potential systems used in audiology and tinnitus clinics that overlap with Lenire's clinical infrastructure.
• SoundCure: SoundCure developed the Serenade tinnitus treatment system, a prescription sound-therapy device that directly competes in the tinnitus device market alongside Lenire for audiologist prescribing and patient outcomes.
• MED-EL: MED-EL produces cochlear implant systems and middle-ear implants used clinically to manage severe tinnitus, providing a partial-overlap, implant-based therapeutic option relevant to Lenire's prescription neuromodulation approach.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/LenireTinnitus
• Facebookfacebook.com/leniretinnitus

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lenire